On Monday, January 15, the next meeting of the Transparency Council.
AOTMiT: The Transparency Council will evaluate, among other things, a drug for plasmocytic myeloma
Published Jan. 12, 2024 13:15
During the session, it was planned:
- Preparation of a position paper on the evaluation of the drug Tecvayli (teclistamabum) under drug program B.54 "Treatment of patients with plasmocytic myeloma (ICD-10: C90.0)".
- Preparation of a position paper on the appropriateness of issuing approvals for reimbursement of the foodstuff for special nutritional use Milupa Basic CaD for the indication: disorders of calcium metabolism in pediatric patients.
- Preparation of an opinion on the draft health policy program of a local government unit co-financed by the EU under the ESF: "Prevention and rehabilitation of persons with musculoskeletal dysfunctions hindering the performance of professional work" implemented by the Malopolska Region.
Source: AOTMiT
